^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Anti-CD22 CAR-T Cells
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Boren Hospital
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
Phase 2
Beijing Boren Hospital
Recruiting
Last update posted :
08/15/2022
Initiation :
05/01/2020
Primary completion :
05/01/2024
Completion :
10/01/2024
ABL1 • CD22
|
CD22 positive • CD22 expression
|
cyclophosphamide • Anti-CD22 CAR-T Cells
Share
